Study summary · research use only
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, the authors examined the pentapeptide ipamorelin (IPA) on insulin secretion from pancreatic tissue fragments of normal and streptozotocin-induced diabetic rats, incubated with concentrations from 10(-12) to 10(-6) M, with insulin measured by radioimmunoassay. They report that ipamorelin was associated with significant increases in insulin secretion from both normal and diabetic pancreas (p<0.04), and that diltiazem, yohimbine, propranolol, or a combination of atropine, propranolol, and yohimbine inhibited this secretion (p<0.03); atropine alone reduced it in diabetic but not normal rats. The authors interpret ipamorelin as stimulating insulin release through calcium-channel and adrenergic-receptor pathways and note this as the first such study.
Abstract
To examine the effect of ipamorelin (IPA), a novel pentapeptide with a strong growth hormone releasing potency, on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Diabetes mellitus was induced by streptozotocin (60 mg kg(-1)). Four weeks after the induction of diabetes, pancreatic tissue fragments of normal and diabetic rats were removed and incubated with different concentrations (10(-12) - 10(-6) M) of IPA. Insulin release from the pancreas was measured by radioimmunoassay. Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. Either diltiazem or yohimbine or propranolol or a combination of atropine, propranolol and yohimbine inhibited IPA-evoked insulin secretion significantly (p<0.03) from the pancreas of normal and diabetic rats. Atropine caused a significant (p<0.007) reduction in the IPA-induced insulin secretion in diabetic but not in normal rats. IPA stimulates insulin release through the calcium channel and the adrenergic receptor pathways. This is the first study to examine the effect of ipamorelin on insulin secretion in the pancreas.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.